Search results for " Deferoxamine"

showing 3 items of 3 documents

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspi…

2009

The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control …

MaleThalassemiaKaplan-Meier Estimatelaw.inventionchemistry.chemical_compoundRandomized controlled triallawCause of DeathNeoplasmsDeferiproneProspective StudiesChildCause of deathHazard ratioHematologyMiddle AgedCombined Modality TherapySurvival RateThalassemia survival chelation treatment trial thalassemia majorCombinationSplenectomyMolecular MedicineDrug Therapy CombinationFemaleDeferiproneAdultmedicine.medical_specialtyAdolescentPyridonesDeferoxamineIron Chelating AgentsYoung AdultDrug TherapyInternal medicinemedicineHumansBlood TransfusionAdolescent; Adult; Blood Transfusion; Cause of Death; Chelation Therapy; Child; Combined Modality Therapy; Deferoxamine; Drug Therapy; Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Kaplan-Meiers Estimate; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prospective Studies; Pyridones; Splenectomy; Survival Rate; Young Adult; beta-ThalassemiaMolecular BiologySurvival rateKaplan-Meiers EstimateSurvival analysisProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modelbeta-ThalassemiaCell Biologymedicine.diseaseChelation TherapySurgerychemistrybusiness
researchProduct

Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subse…

2018

Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown. The objective of this study was to obtain evidence on whether TSAT determines the impact of experimental ischemic stroke on brain damage and whether iron-free transferrin (apotransferrin, ATf)-induced reduction of TSAT is neuroprotective. We found that experimental ischemic stroke promoted an early extravasation of circulating iron-loaded transferrin (holotransferrin, HTf) to the ischemic brain parenchyma.…

0301 basic medicineU-PAGE urea-polyacrylamide gel electrophoresisMaleClinical BiochemistryExperimental strokeBiochemistryBrain IschemiaBrain ischemia0302 clinical medicineADC apparent diffusion coefficientApotransferrinDWI diffusion-weighted imagingTANDEM-1 Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion clinical trialrHTf rat HTfrATf rat ATflcsh:QH301-705.5chemistry.chemical_classificationNeuronslcsh:R5-920ChemistryTransferrinExtravasationNS21 a medium supplement to grow neuronspDAPK-1 phosphorylated anti-death-associated protein kinase 1NeuroprotectionStrokeWB Western blotFemalemedicine.symptomlcsh:Medicine (General)Research PaperhHTf human HTfPC12 cell line derived from a pheochromocytoma of the rat adrenal medullamedicine.medical_specialtyIron OverloadBBB blood-brain barrierNMDAR N-methyl-D-aspartate receptorDCF dihydrofluoresceinIronWGA wheat germ agglutininHTf holotransferrinTransferrin receptorBrain damageTfR transferrin receptorDeferoxamineNeuroprotectionPI propidium iodide03 medical and health sciencesBrain damageCM conditioned mediumROS reactive oxygen speciesInternal medicine4-HNE 4-hydroxynonenalTf transferrinReceptors TransferrinmedicineFeRhoNoxTM-1 probe to detect Fe2+AnimalsHumansATf apotransferrinCM-H2DCFDA 5-chloromethyl-27-dichlorodihydrofluorescein diacetateMCAO middle cerebral artery occlusionDMT-1 divalent metal transporterB-27 a medium supplement to grow neuronsReactive oxygen speciesNMDA N-methyl-D-aspartateTSAT blood transferrin saturationTransferrin saturationBlood transferrin saturation (TSAT)Organic ChemistryNIR near infraredReactive oxygen species (ROS)medicine.diseasepMCAO permanent middle cerebral artery occlusionRatsPWI perfusion-weighted imaging030104 developmental biologyEndocrinologylcsh:Biology (General)TransferrinDAPK-1 anti-death-associated protein kinaseOGD oxygen/glucose deprivationTTC 235-triphenyl-tetrazolium chlorideLipid PeroxidationMCA middle cerebral arteryApoproteinsReactive Oxygen SpeciesMRI magnetic resonance imagingtMCAO transient middle cerebral artery occlusion030217 neurology & neurosurgeryhATf human ATf
researchProduct

Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major

2013

Transfusion and iron chelation treatment have significantly reduced morbidity and improved survival of patients with thalassemia major. However, cardiac disease continues to be the most common cause of death. We report the left-ventricular ejection fraction, determined by echocardiography, in one hundred sixtyeight patients with thalassemia major followed for at least 5 years who received continuous monotherapy with deferoxamine (N = 108) or deferiprone (N = 60). The statistical analysis, using the generalized estimating equations model, indicated that the group treated with deferiprone had a significantly better left-ventricular ejection fraction than did those treated with deferoxamine (c…

AdultMalemedicine.medical_specialtyIron OverloadHeart DiseasesPyridonesThalassemiaDeferoxamineIron Chelating AgentsVentricular Function Leftlaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicineHumansMedicineDeferiproneIn patientYoung adultMolecular BiologyThalassemia major Left ventricular ejection fraction (LVEF) Deferiprone Deferoxamine Echocardiography ChelationRetrospective StudiesEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeRetrospective cohort studyCell BiologyHematologymedicine.diseaseDeferoxamineTreatment OutcomechemistryCardiologyMolecular MedicineFemalebusinessDeferipronemedicine.drug
researchProduct